markets.businessinsider.com
Teva, Sanofi present new results from RELIEVE UCCD Phase 2b study
New Phase 2b data were presented for duvakitug, an investigational antibody for UC and Crohn’s disease; people with IBD may see this as a potential future treatment option if later trials are positive. The report focuses on tolerability and that no emergent safety signals were seen in the study cohorts.
Further detailed efficacy and safety data are needed before clinical impact is known.
Patients with moderate-to-severe ulcerative colitis or Crohn’s disease, clinicians treating IBD, researchers following new biologic therapies, and people tracking IBD drug development or clinical trials.
What To Know
Teva and Sanofi presented detailed Phase 2b results for duvakitug (an anti‑TL1A monoclonal antibody) from the RELIEVE UCCD study, reported at ECCO. The article says the drug was generally well tolerated in both UC and CD cohorts and that no new safety signals or dose‑dependent adverse event patterns were observed.
This is a report about company‑presented Phase 2b trial data for an investigational biologic (duvakitug) targeting TL1A, shared at a scientific conference.
The source is a market/financial news summary referencing presentations at ECCO rather than a peer‑reviewed paper; it focuses on tolerability and that results were presented, not on detailed efficacy outcomes or numeric results.
If you want details: look for the original ECCO abstracts or conference slides, or company press releases from Teva or Sanofi, which are more likely to include efficacy numbers, subgroup analyses, and full safety tables.
Caveats: This article is a business/markets writeup summarizing conference presentations; it does not provide full trial data, endpoints, or statistical results and should not be used to guide treatment decisions.
This is a conference summary reported by a financial news service. Conference presentations and company summaries often precede full peer‑reviewed publication and regulatory review. The article emphasizes tolerability but does not include efficacy numbers or long‑term safety data; seek the ECCO abstract or companies’ scientific materials for full information.
